Holen Sie sich die Stockscreener-App
13.18
1.20%
-0.16
Handel nachbörslich:
13.38
0.20
+1.52%
Schlusskurs vom Vortag:
$13.34
Offen:
$13.34
24-Stunden-Volumen:
2.01M
Relative Volume:
1.12
Marktkapitalisierung:
$1.61B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-6.9005
EPS:
-1.91
Netto-Cashflow:
$-33.45M
1W Leistung:
-17.11%
1M Leistung:
-14.64%
6M Leistung:
-47.30%
1J Leistung:
-68.75%
1-Tages-Spanne:
$12.96
$13.46
1-Wochen-Bereich:
$12.96
$16.34
52-Wochen-Spanne:
$12.96
$57.90
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TXG | 13.18 | 1.61B | 631.73M | -239.78M | -33.45M | -1.91 |
| VEEV | 213.68 | 34.73B | 2.57B | 615.26M | 996.76M | 3.32 |
| SOLV | 67.12 | 11.43B | 8.25B | 404.00M | 1.52B | 0.00 |
| DOCS | 52.21 | 9.58B | 493.63M | 160.55M | 162.20M | 0.55 |
| HQY | 102.40 | 8.82B | 1.10B | 105.67M | -197.98M | 0.1475 |
| TEM | 54.06 | 8.51B | 640.44M | -743.28M | -206.93M | 0.00 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10x Genomics (NASDAQ:TXG) Hits New 52-Week LowWhat's Next? - MarketBeat
10X Genomics stock hits 52-week low at $13.98 amid market shifts - Investing.com
Relative Strength Alert For 10x Genomics - Nasdaq
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Baillie Gifford & Co. - MarketBeat
10X Genomics' SWOT analysis: genomics firm's stock faces headwinds, eyes recovery - Investing.com
Sumitomo Mitsui Trust Group Inc. Grows Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Nikko Asset Management Americas, Inc. Expands Stake in 10x Genomics Inc. - GuruFocus.com
TXG10x Genomics, Inc. Latest Stock News & Market Updates - StockTitan
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference - BioSpace
ARK Investment Management LLC Purchases 1,436,582 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference – Company Announcement - Financial Times
10x Genomics Announces Preliminary Select Third Quarter 2024 Res - GuruFocus.com
10x Genomics Reports Third Quarter 2024 Financial Results - GuruFocus.com
10x Genomics Announces Mega-Scale Single Cell Analysis for One C - GuruFocus.com
Sumitomo Mitsui Trust Group's Strategic Acquisition in 10x Genomics Inc - GuruFocus.com
10x Genomics Inc (TXG) Trading 2.45% Higher on Nov 4 - GuruFocus.com
Barclays Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Brokers Set Expectations for 10x Genomics FY2024 Earnings - MarketBeat
Allspring Global Investments Holdings LLC Has $880,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative - PR Newswire
10x Genomics, Inc. (NASDAQ:TXG) Q3 2024 Earnings Call Transcript - Insider Monkey
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigat - GuruFocus.com
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results - Benzinga
10x Genomics Inc (TXG) Trading 4.91% Higher on Oct 30 - GuruFocus.com
Citigroup Cuts 10x Genomics (NASDAQ:TXG) Price Target to $23.00 - MarketBeat
Canaccord keeps 10X Genomics shares at Buy list - Investing.com
10x Genomics (NASDAQ:TXG) Issues Earnings Results - MarketBeat
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics Reports Mixed Q3 2024 Results - TipRanks
10x Genomics: Q3 Earnings Snapshot - The Advocate
10x Genomics shares sink 7% on revenue miss, lowered outlook - Investing.com
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
10x Genomics falls 7% on 2024 revenue guidance cut - MSN
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Inc Reports Q3 2024 Revenue of $151.7 Million, Missing Estimates; Gross Margin Improves to 70% - GuruFocus.com
10x Genomics shares sink 7% on revenue miss, lowered outlook By Investing.com - Investing.com UK
10x Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
10x Genomics Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell - Yahoo Finance
10X Genomics' SWOT analysis: stock faces headwinds amid strong consumables demand - Investing.com India
Lecap Asset Management Ltd. Purchases Shares of 38,829 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why - Yahoo Finance
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan
10x Genomics (TXG) Set to Announce Earnings on Tuesday - MarketBeat
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs?Major Drivers - Smartkarma
Proteintech Genomics Launches the MultiPro® Human Discovery Panel: A New Frontier in Single-Cell Multiomics - Business Wire
NanoString and Bird & Bird triumph against 10x Genomics at central division - JUVE Patent
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):